News › Industry News, News

Eli Lilly’s Mounjaro, Zepbound Back in Stock After Extended Shortage, FDA Says

August 7, 2024
Injection pens and sugar cubes

Months of an ongoing supply squeeze for Eli Lilly’s tirzepatide-based meds have lifted, according to the FDA.

After placing nearly all doses of the company’s diabetes drug Mounjaro and its obesity counterpart Zepbound on the agency’s shortage list in April, all doses of the meds are now listed as available. Mounjaro’s first appearance on the list was all the way back in 2022.

The shortage, which has been attributed to fervent demand outweighing supply, has caused the company to pour billions into extra supply capacity. By the end of the first quarter, seven sites expected to help ease the supply woes were either “ramping up or under construction,” chief financial officer Anat Ashkenazi said on a previous earnings call.

Read more at Fierce Pharma >>

Become a member

Get the tools you need to succeed in the medical spa industry.

Related
    • Allergan Aesthetics’ Skinvive by Juvéderm Receives FDA Approval for the Improvement of Neck Appearance
    • Obagi Medical Announces FDA Approval of Obagi saypha ChIQ Injectable Hyaluronic Acid Gel
    • MedSafe Becomes Gold Vendor Affiliate with the American Med Spa Association
    • FDA Approves First New Sunscreen Ingredient in 20 Years
    • Allergan Aesthetics Releases ‘The Aesthetics Evolution: What Consumers Really Want’ Highlighting Consumer Motivations and Expectations in Aesthetics